Bill Ackman, head of the best performing large hedge fund firm, is poised to pull in at least $1 billion, according to rough CNBC calculations using his net worth, stake in $19 billion Pershing Square Capital Management and the fund’s stellar 35 percent return net of fees through early December. Show More Summary
A new lawsuit accuses hedge fund manager Bill Ackman and Canadian firm Valeant Pharmaceuticals International Inc. of insider trading in Allergan Inc. stock before their unsuccessful bid to acquire the Botox maker.
Bill Ackman sat in the hair and makeup chair at Bloomberg, waiting for his lieutenants to file in for a quick briefing before he went on the air. He knew what they were going to say and what they needed to hear him say before they’dShow More Summary
Bill Ackman, who runs Pershing Square Capital, has released an internal Herbalife video from 2005 that he says shows a top distributor talking about deceptive recruiting practices. According to Pershing Square, the video is from a 2005...Show More Summary
Hedge fund manager Bill Ackman of Pershing Square was just on Bloomberg TV's "Market Makers" talking about his infamous Herbalife short. "We've actually come up with some new stuff," Ackman said before showing a clip of an internal Herbalife...Show More Summary
My afternoon train reads: • WTF?!? Jack Bogle: I Wouldn’t Risk Investing Outside the U.S. (Bloomberg) • A Dozen Things I’ve Learned From Bill Ackman about Value and Activist Investing (25iq) • China Has Overtaken the U.S. as the World’s Largest Economy (Vanity Fair) • The Trouble With Cheap Oil (New Yorker) • Recession Is The New ‘Stimulus’ (Alhambra...Read More
During the past few years, investors like Carl Icahn, Bill Ackman and Nelson Peltz have become hugely influential forces in the marketplace. Politely called "activist investors"—we can't print... To view the full story, click the title link.
For those who care what Bill Ackman has been thinking and doing lately, aside from colluding with and piggybacking on desperate for M&A "strategics" to go activist, and buying a boatload of calls in advance of announcing a material, market-moving position and in the process generating a 43.4% YTD return while the SEC sits on its hands. Show More Summary
Hundreds of financial journalists spent their Friday evening at the "Financial Follies"—an annual black tie gathering at the Marriott Marquis in Times Square. The Follies, which is hosted by the New York Financial Writers Association, always includes a staged musical show that pokes fun at some of the year's big business news stories. Show More Summary
This has been a very difficult and humbling year for most hedge fund managers. But billionaire William Ackman is doing great, distinguishing himself as the hedge fund manager of 2014 by trouncing just about all big shot money managers and the U.S. stock market with a series of bold and closely-watched bets that have performed very well.
The Pershing Square chief is back on for dinner at Marea on Dec. 18, while Valeant Pharmaceuticals will have to settle for about $400 million of his winnings and maybe some other sacrificial lamb-drug company that Ackman might care to throw its way. Show More Summary
The $45 bln drug company’s tilt at Allergan alongside Bill Ackman’s Pershing Square leaves it with just a modest windfall to show for a seven-month campaign that risked legally questionable tactics. Valeant boss Michael Pearson’s M&A experiment is not one to repeat.
Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) could lose out on a deal to acquire Botox Maker Allergan, Inc. (NYSE:AGN) if it does not move with speed and increase its proposed $54 billion takeover bid. Allergan has already held talks with Irish-based Actavis plc (NYSE:ACT) over a potential $60 billion merger. Bill Ackman of Pershing Square stands […]
In April, hedge fund billionaire stepped onto a Manhattan stage to launch his backing of ’ effort to purchase Botox-maker. During his presentation, Ackman emphasized the durable nature of both Valeant and ’s products, brands that are not going away and don’t depend on a patent. Ackman cited a couple of other companies that […]
About 40% of Bill Ackman's hedge fund, Pershing Square, is made up of his stake in Allergan. He's been using his stake to pressure the company to sell itself to another pharmaceutical company, Valeant, to buy. Now that whole deal could...Show More Summary
Bill Ackman's latest investment is in Zoetis, an animal health business with more than $4 billion in annual sales.
As it was previously rumored in many sources, Bill Ackman‘s Pershing Square took a massive position in Zoetis Inc (NYSE:ZTS), as reported in a new filing with the US Securities and Exchange Commission. Pershing Square currently owns some 41.82 million shares, which represent 8.3% of the company’s outstanding stock. The stake is activist by nature and […]
Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.